Bacteriophage Dosing and Its Effect on Bacterial Growth Suppression in a Staphylococcus epidermidis Model: An In Vitro Study.

PHAGE (New Rochelle, N.Y.) Pub Date : 2024-12-18 eCollection Date: 2024-12-01 DOI:10.1089/phage.2024.0001

Jason Young, Mohammad Javad Shariyate, Ahmad Hedayatzadeh Razavi, Ara Nazarian, Edward K Rodriguez

{"title":"Bacteriophage Dosing and Its Effect on Bacterial Growth Suppression in a Staphylococcus epidermidis Model: An In Vitro Study.","authors":"Jason Young, Mohammad Javad Shariyate, Ahmad Hedayatzadeh Razavi, Ara Nazarian, Edward K Rodriguez","doi":"10.1089/phage.2024.0001","DOIUrl":null,"url":null,"abstract":"Background: Phages are an emerging therapy in the treatment of prosthetic joint infections, though many challenges remain, including an incomplete understanding of optimal phage dosing.Materials and methods: We performed an in vitro assessment of how phage dosing as measured by multiplicity of infection (MOI) impacts bacterial growth in planktonic and biofilm conditions using a Staphylococcus epidermidis model. Staphylococcus epidermidis ATCC 35984 was combined in planktonic and biofilm forms with phage vB_SepM_Alex at varying concentrations, and growth was monitored via spectrophotometry.Results: Planktonic bacterial growth was significantly higher when MOI ≤ 0.01 compared with MOI ≥ 10 (p < 0.05). Biofilms with phage dosing at ≤ 104 plaque-forming units (PFU)/mL had significantly greater spectrophotometer readings than those dosed at 1010 PFU/mL (p < 0.05).Conclusions: Our findings suggest lower, not higher, phage dosing is associated with greater bacterial persistence. Our study helps inform the dosing and delivery of this alternative form of antibiosis.","PeriodicalId":74428,"journal":{"name":"PHAGE (New Rochelle, N.Y.)","volume":"5 4","pages":"223-229"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876813/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PHAGE (New Rochelle, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/phage.2024.0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Phages are an emerging therapy in the treatment of prosthetic joint infections, though many challenges remain, including an incomplete understanding of optimal phage dosing.

Materials and methods: We performed an in vitro assessment of how phage dosing as measured by multiplicity of infection (MOI) impacts bacterial growth in planktonic and biofilm conditions using a Staphylococcus epidermidis model. Staphylococcus epidermidis ATCC 35984 was combined in planktonic and biofilm forms with phage vB_SepM_Alex at varying concentrations, and growth was monitored via spectrophotometry.

Results: Planktonic bacterial growth was significantly higher when MOI ≤ 0.01 compared with MOI ≥ 10 (p < 0.05). Biofilms with phage dosing at ≤ 10⁴ plaque-forming units (PFU)/mL had significantly greater spectrophotometer readings than those dosed at 10¹⁰ PFU/mL (p < 0.05).

Conclusions: Our findings suggest lower, not higher, phage dosing is associated with greater bacterial persistence. Our study helps inform the dosing and delivery of this alternative form of antibiosis.

查看原文本刊更多论文

噬菌体剂量及其对表皮葡萄球菌模型细菌生长抑制作用的体外研究

背景：噬菌体是治疗假体关节感染的一种新兴疗法，尽管仍存在许多挑战，包括对最佳噬菌体剂量的不完全了解。材料和方法：我们使用表皮葡萄球菌模型对浮游和生物膜条件下噬菌体剂量（通过感染多样性（MOI）测量）如何影响细菌生长进行了体外评估。将表皮葡萄球菌ATCC 35984与噬菌体vB_SepM_Alex以不同浓度的浮游和生物膜形式结合，通过分光光度法监测其生长情况。结果：与MOI≥10相比，MOI≤0.01时浮游细菌生长显著增加（p < 0.05）。噬菌体剂量≤104 PFU/mL的生物膜的分光光度计读数显著高于1010 PFU/mL的生物膜（p < 0.05）。结论：我们的研究结果表明，较低而不是较高的噬菌体剂量与较强的细菌持久性相关。我们的研究有助于告知这种替代形式的抗生素的剂量和递送。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PHAGE (New Rochelle, N.Y.)

自引率

0.00%

发文量